Amylin Pharmaceuticals Shares Soar over 45% (AMLN, VICL, AGN, TEVA, PFE, VRML)
Amylin Pharmaceuticals Inc (NASDAQ:AMLN) soared 45.09% to $22.33. According to Bloomberg reports, the Company had rejected an unsolicited $3.5 billion or $22 a share takeover bid from Bristol-Myers Squibb. Amylin is discussing possible partnerships with several large drug companies for its overseas drugs. The price is 43 percent more than Amylin’s closing stock price of $15.39 yesterday. The $3.5 billion figure, based on 160.8 million Amylin shares outstanding, excludes debt.
However, analyst at Piper Jaffray downgraded the rating on the stock from overweight to neutral.
Vical Incorporated (NASDAQ:VICL) climbed up 3.31% to $3.43. The Company said that researchers at Ehime University in Japan and their collaborators have developed a Vaxfectin. This is a formulated DNA vaccine candidate with the potential to prevent transmission of malaria.
Allergan Inc (NYSE:AGN) declined 0.17% to $94.15. The Company announced successful results from the two Phase III clinical trials of BOTOX as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.
Teva Pharmaceutical Industries Ltd (ADR)(NASDAQ:TEVA) is down 0.77% to $43.73. The FDA has approved Qnasl Nasal Aerosol of Teva Pharmaceutical Industries. This is a new dry nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.
Pfizer Inc (NYSE:PFE) decreased 0.67% to $22.35. The stock is up after Goldman Sachs analysts said the Company might go beyond the divestiture plans it has already announced.
Vermillion Inc (NASDAQ:VRML) jumped up 23.16% to $2.18. The Company has received a notice of allowance from the United States Patent and Trademark Office for a patent. This patent further expands the list of biomarkers Vermillion has employed in the diagnosis or status determination of ovarian cancer.